4/A: Bio-Techne Executive Awarded Performance Restricted Stock Units

Bio-Techne Corp's President of Diagnostics and Genomics, Matthew McManus, was granted 15,825 performance-based restricted stock units, vesting in 2027 upon achievement of performance goals.

Summary

• Matthew McManus, President of Diagnostics and Genomics at Bio-Techne Corp, received 15,825 performance restricted stock units.
• These units will vest on August 15, 2027, if certain performance goals are met, or at a later date when performance is certified.
• Each restricted stock unit represents the right to receive one share of Bio-Techne common stock.
• This filing is an amendment to a previous filing to correct the number of performance restricted stock units granted.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a positive alignment of interests between management and shareholders. The amendment is a minor correction and does not indicate any negative issues.

Positives

• The grant of performance-based restricted stock units aligns executive compensation with company performance.
• The vesting period of 2027 encourages long-term focus and commitment from the executive.

Risks

• The vesting of the stock units is contingent on achieving performance goals, which may not be met.
• The value of the stock units is subject to the market price of Bio-Techne common stock, which can fluctuate.

Future Outlook

The restricted stock units will vest in 2027 if performance goals are achieved, aligning executive compensation with long-term company performance.

Industry Context

The granting of performance-based stock units is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Many biotechnology companies use performance-based equity awards to motivate executives, similar to Bio-Techne's approach.
• Companies like Thermo Fisher Scientific and Danaher also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting period of 3 years is fairly standard for performance-based equity awards in the industry.

Stakeholder Impact

• Shareholders may view this as a positive sign that executive compensation is tied to company performance.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates

Keywords

restricted stock units, performance-based compensation, executive compensation, stock options, Bio-Techne, Matthew McManus